Danish Pharmacovigilance Update, 15 December 2011
03 January 2012
You must accept marketing cookies to share the page by mail
Update consent
...
Atomoxetine (Strattera®) and the risk of increased blood pressure and heart rate, front page
Increased suspicion of risk of congenital malformations with the antiepileptic topiramate (Topimax® and others), front page
Pradaxa® capsules are NOT to be opened, page 2
New recommendations for the antidepressant escitalopram, page 2
Tibolone and a potential risk of thromboembolisms, myocardial infarction, breast cancer and ovarian cancer, page 3
Rosuvastatin and the risk of gynaecomastia, page 3
In October, the Danish Medicines Agency received two reports involving cases of lactic acidosis in patients undergoing treatment with metformin for the treatment of type 2 diabetes, page 4
Consumption analysis of Daxas® for COPD patients with known depression, page 5
Childhood vaccinations and adverse reactions in the third quarter of 2011, page 6
Gender differences in adverse reaction reports, page 8
When is it important for doctors to report adverse reactions to the Danish Medicines Agency? Back page
